期刊
DNA REPAIR
卷 61, 期 -, 页码 25-36出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.dnarep.2017.11.004
关键词
PARP; PARG; Tankyrase; Radiosensitization; Homologous recombination; Non-homologous end-joining
资金
- Breast Cancer Now [PR016]
- CRUK [C5759/A17098]
- Welcome Trust grant [WT093134AIA]
- MRC SHIMA award [MR/K015753/1]
- MRC [MR/K015753/1] Funding Source: UKRI
Upon DNA binding the poly(ADP-ribose) polymerase family of enzymes (PARPs) add multiple ADP-ribose subunits to themselves and other acceptor proteins. Inhibitors of PARPs have become an exciting and real prospect for monotherapy and as sensitizers to ionising radiation (IR). The action of PARPs are reversed by poly (ADP-ribose) glycohydrolase (PARG). Until recently studies of PARG have been limited by the Slack of an inhibitor. Here, a first in class, specific, and cell permeable PARG inhibitor, PDD00017273, is shown to radio sensitize. Further, PDD00017273 is compared with the PARP1/2/3 inhibitor olaparib. Both olaparib and PDD00017273 altered the repair of IR-induced DNA damage, resulting in delayed resolution of RAD51 foci compared with control cells. However, only PARG inhibition induced a rapid increase in IR-induced activation of PRKDC (DNA-PK) and perturbed mitotic progression. This suggests that PARG has additional functions in the cell compared with inhibition of PARP1/2/3, likely via reversal of tankyrase activity and/or that inhibiting the removal of poly(ADP-ribose) (PAR) has a different consequence to inhibiting PAR addition. Overall, our data are consistent with previous genetic findings, reveal new insights into the function of PAR metabolism following IR and demonstrate for the first time the therapeutic potential of PARG inhibitors as radiosensitizing agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据